ArticleScientific reports2025
Acrylamide coadministration modulates hepatic ROS-mediated apoptotic DNA damage and inflammation induced by TiO
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The widespread human consumption of food and commercial products containing acrylamide and titanium dioxide (TiO2) nanoparticles highlights the need to assess the risks of their concurrent exposure. However, almost no studies have explored the effect of acrylamide and TiO2 nanoparticles co-exposure on genomic DNA integrity and inflammation induction in hepatic tissues. Consequently, this study aimed to estimate the impact of acrylamide and TiO2 nanoparticles coadministration on the genomic DNA integrity, reactive oxygen species (ROS) generation and expression level of apoptotic and inflammatory genes in mice hepatic tissues. Mice were orally administered acrylamide (3 mg/kg) or/and TiO2 nanoparticles (5 mg/kg) five times a week over two successive weeks. Genomic DNA integrity was assessed using alkaline Comet and Laddered DNA fragmentation assays, while ROS level was measured using 2, 7- Dichlorofluorescein diacetate dye. The expression level of inflammatory and apoptotic genes was quantified using quantitative real-time PCR (qRT-PCR). The results indicated that either acrylamide (3 mg/kg) or TiO2 nanoparticles (5 mg/kg) alone significantly disrupted DNA integrity, increased ROS level, and upregulated inflammatory (INOS, COX-2) and apoptotic (p53) gene expression, while downregulating the anti-inflammatory HO-1 gene. However, the coadministration of acrylamide and TiO2 nanoparticles resulted in even greater DNA damage, higher ROS production, and a further increase in inflammatory and apoptotic gene expression, along with a more pronounced decrease in HO-1 expression compared to the effects of either agent alone. In conclusion these findings suggest that chronic coadministration of acrylamide and TiO2 nanoparticles, even at low doses, amplifies the genomic DNA damage and inflammation induced by each agent individually, exacerbating hepatic cell stress. Therefore, avoiding simultaneous exposure to acrylamide and TiO2 nanoparticles is recommended to reduce the risk of severe toxic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.